AstraZeneca to pay $50 million for Amgen assets

Monday 2 April 2012

AstraZeneca Plc is to pay $50 million upfront to Amgen Inc in a deal where the two companies will jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio. AZ announced the agreement on 2 April.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom